978 Stock Overview
A clinical stage biotechnology company, engages in the research, development, and production of monoclonal antibody drugs for cancers in the People’s Republic of China. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 1 more risk
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
Adagene Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.37 |
| 52 Week High | US$3.16 |
| 52 Week Low | US$1.19 |
| Beta | 0.61 |
| 1 Month Change | -2.84% |
| 3 Month Change | -19.41% |
| 1 Year Change | -31.16% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -93.18% |
Recent News & Updates
Recent updates
Shareholder Returns
| 978 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 13.2% | 0.6% | 1.7% |
| 1Y | -31.2% | -12.2% | 12.8% |
Return vs Industry: 978 underperformed the German Biotechs industry which returned -13.8% over the past year.
Return vs Market: 978 underperformed the German Market which returned 13.4% over the past year.
Price Volatility
| 978 volatility | |
|---|---|
| 978 Average Weekly Movement | 10.8% |
| Biotechs Industry Average Movement | 5.9% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in DE Market | 13.0% |
| 10% least volatile stocks in DE Market | 3.1% |
Stable Share Price: 978's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 978's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2011 | 138 | Peizhi Luo | www.adagene.com |
Adagene Inc., a clinical stage biotechnology company, engages in the research, development, and production of monoclonal antibody drugs for cancers in the People’s Republic of China. Its lead product candidate is the ADG126, a masked fully-human anti-CTLA-4 mAb which is in phase 1b/2 clinical development for the treatment of cancer. The company also develops ADG116, a fully human anti-CTLA-4 antibody generated using NEObody technology, which is in phase 1b/2 clinical trials to treat advanced/metastatic solid tumors; ADG206, which is in phase 1 clinical development to treat advanced metastatic solid tumors; ADG104, anti-PD-L1 monoclonal antibody which is in phase 2 clinical development; and ADG125, a novel anti-CSF-1R mAb which is in Phase 2 clinical development.
Adagene Inc. Fundamentals Summary
| 978 fundamental statistics | |
|---|---|
| Market cap | €66.22m |
| Earnings (TTM) | -€29.55m |
| Revenue (TTM) | €91.23k |
730.4x
P/S Ratio-2.3x
P/E RatioIs 978 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 978 income statement (TTM) | |
|---|---|
| Revenue | US$103.20k |
| Cost of Revenue | US$0 |
| Gross Profit | US$103.20k |
| Other Expenses | US$33.53m |
| Earnings | -US$33.42m |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.71 |
| Gross Margin | 100.00% |
| Net Profit Margin | -32,386.45% |
| Debt/Equity Ratio | 36.0% |
How did 978 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/07 15:52 |
| End of Day Share Price | 2025/05/07 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Adagene Inc. is covered by 6 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Bing Zhao | China Renaissance Securities |
| Ziyi Chen | Goldman Sachs |
| Yu He | H.C. Wainwright & Co. |